drugset
drugset / Trial / NCT06673693

Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma

NCT06673693 ↗

Phase 2 Recruiting 24 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

Exploring the efficacy and safety of Tislelizumab combined with stereotactic body radiation therapy (SBRT) as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (HNSCC).

Timeline

Start
2025-04-15
Primary completion
2027-12-31
Completion
2029-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous

Indications

head and neck squamous cell carcinoma